Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2925)
All Articles published online
|
Sep 15, 2004 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ding X, Yang LY, Huang GW, Wang W, Lu WQ. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 2004; 10(18): 2735-2739 [PMID: 15309730 DOI: 10.3748/wjg.v10.i18.2735] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v10/i18/2735.htm |
| Number | Citing Articles |
| 1 |
Shuhong Shao, Zunling Li, Wei Gao, Guohua Yu, Dexiang Liu, Fang Pan, Pan-Chyr Yang. ADAM-12 as a Diagnostic Marker for the Proliferation, Migration and Invasion in Patients with Small Cell Lung Cancer. PLoS ONE 2014; 9(1): e85936 doi: 10.1371/journal.pone.0085936
|
| 2 |
Michael W.Y. Chan, Yi-Wen Huang, Corinna Hartman-Frey, Chieh-Ti Kuo, Daniel Deatherage, Huaxia Qin, Alfred S.L. Cheng, Pearlly S. Yan, Ramana V. Davuluri, Tim H.-M. Huang, Kenneth P. Nephew, Huey-Jen L. Lin. Aberrant Transforming Growth Factor β1 Signaling and SMAD4 Nuclear Translocation Confer Epigenetic Repression of ADAM19 in Ovarian Cancer. Neoplasia 2008; 10(9): 908 doi: 10.1593/neo.08540
|
| 3 |
Mohamed I. Saad, Brendan J. Jenkins. The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond. The FEBS Journal 2024; 291(1): 10 doi: 10.1111/febs.16923
|
| 4 |
Xian-Ming Lin, Ying-Bin Liu, Fan Zhou, Yu-Lian Wu, Li Chen, He-Qing Fang. Expression of tumor necrosis factor-alpha converting enzyme in liver regeneration after partial hepatectomy. World Journal of Gastroenterology 2008; 14(9): 1353-1357 doi: 10.3748/wjg.14.1353
|
| 5 |
Xiang-jun Wang, Chang-wei Feng, Min Li. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Molecular and Cellular Biochemistry 2013; 380(1-2): 57 doi: 10.1007/s11010-013-1657-z
|
| 6 |
J-W Kornfeld, S Meder, M Wohlberg, R E Friedrich, T Rau, L Riethdorf, T Löning, K Pantel, S Riethdorf. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. British Journal of Cancer 2011; 104(1): 138 doi: 10.1038/sj.bjc.6606017
|
| 7 |
Patricia M. McGowan, Bríd M. Ryan, Arnold D.K. Hill, Enda McDermott, Niall O'Higgins, Michael J. Duffy. ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression. Clinical Cancer Research 2007; 13(8): 2335 doi: 10.1158/1078-0432.CCR-06-2092
|
| 8 |
Wei-Chih Tsai, Paul Wei-Che Hsu, Tsung-Ching Lai, Gar-Yang Chau, Ching-Wen Lin, Chun-Ming Chen, Chien-Der Lin, Yu-Lun Liao, Jui-Ling Wang, Yat-Pang Chau, Ming-Ta Hsu, Michael Hsiao, Hsien-Da Huang, Ann-Ping Tsou. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49(5): 1571 doi: 10.1002/hep.22806
|
| 9 |
Bhagya N., Chandrashekar K.R.. Tetrandrine and cancer – An overview on the molecular approach. Biomedicine & Pharmacotherapy 2018; 97: 624 doi: 10.1016/j.biopha.2017.10.116
|
| 10 |
Joaquín Arribas, Joan J. Bech-Serra, Belén Santiago-Josefat. ADAMs, cell migration and cancer. Cancer and Metastasis Reviews 2006; 25(1): 57 doi: 10.1007/s10555-006-7889-6
|
| 11 |
Youwen Zhang, Xiaohan Chen, Golbarg M. Roozbahani, Xiyun Guan. Rapid and sensitive detection of the activity of ADAM17 using a graphene oxide-based fluorescence sensor. The Analyst 2019; 144(5): 1825 doi: 10.1039/C8AN02344A
|
| 12 |
Madduri Srinivasarao, Philip S. Low. Ligand-Targeted Drug Delivery. Chemical Reviews 2017; 117(19): 12133 doi: 10.1021/acs.chemrev.7b00013
|
| 13 |
Eva Schlecker, Nathalie Fiegler, Annette Arnold, Peter Altevogt, Stefan Rose-John, Gerhard Moldenhauer, Antje Sucker, Annette Paschen, Elke Pogge von Strandmann, Sonja Textor, Adelheid Cerwenka. Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell–Activating Receptor NKp30. Cancer Research 2014; 74(13): 3429 doi: 10.1158/0008-5472.CAN-13-3017
|
| 14 |
Hye-Won Na, Won-Sik Shin, Andreas Ludwig, Seung-Taek Lee. The Cytosolic Domain of Protein-tyrosine Kinase 7 (PTK7), Generated from Sequential Cleavage by a Disintegrin and Metalloprotease 17 (ADAM17) and γ-Secretase, Enhances Cell Proliferation and Migration in Colon Cancer Cells. Journal of Biological Chemistry 2012; 287(30): 25001 doi: 10.1074/jbc.M112.348904
|
| 15 |
Yong Li, Zhen Ren, Yu Wang, Ya-Zheng Dang, Bo-Xiang Meng, Guo-Dong Wang, Jing Zhang, Jiao Wu, Ning Wen. ADAM17 promotes cell migration and invasion through the integrin β1 pathway in hepatocellular carcinoma. Experimental Cell Research 2018; 370(2): 373 doi: 10.1016/j.yexcr.2018.06.039
|
| 16 |
Isabel Fabregat. Dysregulation of apoptosis in hepatocellular carcinoma cells. World Journal of Gastroenterology 2009; 15(5): 513-520 doi: 10.3748/wjg.15.513
|
| 17 |
Laia Caja, Patricia Sancho, Esther Bertran, Conrad Ortiz, Jean S. Campbell, Nelson Fausto, Isabel Fabregat. The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms. Biochemical Pharmacology 2011; 82(11): 1583 doi: 10.1016/j.bcp.2011.08.011
|
| 18 |
Conrad Ortiz, Laia Caja, Patricia Sancho, Esther Bertran, Isabel Fabregat. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells. Biochemical Pharmacology 2008; 75(10): 1935 doi: 10.1016/j.bcp.2008.02.015
|
| 19 |
Hiroki Honda, Masaaki Takamura, Satoshi Yamagiwa, Takuya Genda, Ryoko Horigome, Naruhiro Kimura, Toru Setsu, Kentaro Tominaga, Hiroteru Kamimura, Yasunobu Matsuda, Toshifumi Wakai, Yutaka Aoyagi, Shuji Terai. Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-15800-z
|
| 20 |
Kai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, Wolfgang Eberhardt, Michel Mittelbronn, Patrick N. Harter, Eva Juengel, Roman Blaheta, Josef Pfeilschifter, Paul Gutwein. MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients. Neoplasia 2013; 15(2): 218 doi: 10.1593/neo.121222
|
| 21 |
Dorte Stautz, Sarah Louise Dombernowsky, Marie Kveiborg. Matrix Proteases in Health and Disease. 2012; : 299 doi: 10.1002/9783527649327.ch12
|
| 22 |
Vikash Reebye, Pål Saetrom, Paul J. Mintz, Kai-Wen Huang, Piotr Swiderski, Ling Peng, Cheng Liu, Xiaoxuan Liu, Steen Lindkaer-Jensen, Dimitris Zacharoulis, Nikolaos Kostomitsopoulos, Noriyuki Kasahara, Joanna P. Nicholls, Long R. Jiao, Madhava Pai, Duncan R. Spalding, Malkhaz Mizandari, Tinatin Chikovani, Mohamed M. Emara, Abdelali Haoudi, Donald A. Tomalia, John J. Rossi, Nagy A. Habib. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesisin vivo. Hepatology 2014; 59(1): 216 doi: 10.1002/hep.26669
|
| 23 |
M A Avila, C Berasain, B Sangro, J Prieto. New therapies for hepatocellular carcinoma. Oncogene 2006; 25(27): 3866 doi: 10.1038/sj.onc.1209550
|
| 24 |
Belé;n Santiago-Josefat, Cary Esselens, Joan Josep Bech-Serra, Joaquín Arribas. Post-transcriptional Up-regulation of ADAM17 upon Epidermal Growth Factor Receptor Activation and in Breast Tumors. Journal of Biological Chemistry 2007; 282(11): 8325 doi: 10.1074/jbc.M608826200
|
| 25 |
Masaki Yoda, Tokuhiro Kimura, Takahide Tohmonda, Hideo Morioka, Morio Matsumoto, Yasunori Okada, Yoshiaki Toyama, Keisuke Horiuchi, Jean Kanellopoulos. Systemic Overexpression of TNFα-converting Enzyme Does Not Lead to Enhanced Shedding Activity In Vivo. PLoS ONE 2013; 8(1): e54412 doi: 10.1371/journal.pone.0054412
|
| 26 |
Carmen Berasain, María Ujue Latasa, Raquel Urtasun, Saioa Goñi, María Elizalde, Oihane Garcia-Irigoyen, María Azcona, Jesús Prieto, Matías A. Ávila. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers 2011; 3(2): 2444 doi: 10.3390/cancers3022444
|
| 27 |
Sung Woo Hong, Wonhee Hur, Jung Eun Choi, Jung-Hee Kim, Daehee Hwang, Seung Kew Yoon. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Oncotarget 2016; 7(17): 23482 doi: 10.18632/oncotarget.8112
|
| 28 |
Laia Caja, Conrad Ortiz, Esther Bertran, Miguel M. Murillo, M. Jesús Miró-Obradors, Evangelina Palacios, Isabel Fabregat. Differential intracellular signalling induced by TGF-β in rat adult hepatocytes and hepatoma cells: Implications in liver carcinogenesis. Cellular Signalling 2007; 19(4): 683 doi: 10.1016/j.cellsig.2006.09.002
|
| 29 |
Monika Gooz. ADAM-17: the enzyme that does it all. Critical Reviews in Biochemistry and Molecular Biology 2010; 45(2): 146 doi: 10.3109/10409231003628015
|
| 30 |
Josefa Castillo, Elena Erroba, María J. Perugorría, Mónica Santamaría, David C. Lee, Jesús Prieto, Matías A. Avila, Carmen Berasain. Amphiregulin Contributes to the Transformed Phenotype of Human Hepatocellular Carcinoma Cells. Cancer Research 2006; 66(12): 6129 doi: 10.1158/0008-5472.CAN-06-0404
|
| 31 |
Antonio Mazzocca, Gianluigi Giannelli, Salvatore Antonaci. Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2010; 1806(1): 74 doi: 10.1016/j.bbcan.2010.02.002
|
| 32 |
Florian R Fritzsche, Kirsten Wassermann, Monika Jung, Angelika Tölle, Ilka Kristiansen, Michael Lein, Manfred Johannsen, Manfred Dietel, Klaus Jung, Glen Kristiansen. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer 2008; 8(1) doi: 10.1186/1471-2407-8-179
|
| 33 |
Q Wei, M Li, X Fu, R Tang, Y Na, M Jiang, Y Li. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate Cancer and Prostatic Diseases 2007; 10(2): 167 doi: 10.1038/sj.pcan.4500933
|
| 34 |
Xuguang Zheng, Feng Jiang, Mark Katakowski, Steven N. Kalkanis, Xin Hong, Xuepeng Zhang, Zheng Gang Zhang, Hongyan Yang, Michael Chopp. Inhibition of ADAM17 reduces hypoxia‐induced brain tumor cell invasiveness. Cancer Science 2007; 98(5): 674 doi: 10.1111/j.1349-7006.2007.00440.x
|
| 35 |
Zhichao Wu, Guangzhi Wang, Shaoqian Xu, Yang Li, Yu Tian, Hongshuang Niu, Fei Yuan, Fenggang Zhou, Zhen Hao, Yongri Zheng, Qingsong Li, Jianjiao Wang. Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17. Tumor Biology 2014; 35(3): 2205 doi: 10.1007/s13277-013-1293-y
|
| 36 |
Viviana Casagrande, Alessandro Mauriello, Simone Bischetti, Maria Mavilio, Massimo Federici, Rossella Menghini. Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-06439-x
|
| 37 |
Rong Xu, Hai-Feng Kang, Hong-Bin Liu, Jun-Bo Qian. Role of a disintegrin and metalloproteinase 17 in malignant tumors of the digestive system. World Chinese Journal of Digestology 2020; 28(19): 986 doi: 10.11569/wcjd.v28.i19.986
|
| 38 |
Nuray Erin, Tümay İpekçi, Bahar Akkaya, İrem Hicran Özbudak, Mehmet Baykara. Changes in expressions of ADAM9, 10, and 17 as well as α-secretase activity in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2017; 35(1): 36.e15 doi: 10.1016/j.urolonc.2016.08.010
|
| 39 |
Maritza P. Garrido, Christopher Vallejos, Silvanna Girardi, Fernando Gabler, Alberto Selman, Fernanda López, Margarita Vega, Carmen Romero. NGF/TRKA Promotes ADAM17-Dependent Cleavage of P75 in Ovarian Cells: Elucidating a Pro-Tumoral Mechanism. International Journal of Molecular Sciences 2022; 23(4): 2124 doi: 10.3390/ijms23042124
|
| 40 |
Giuseppe Carruba, Vitale Miceli, Letizia Cocciadiferro, Maurizio Zarcone, Biagio Agostara, Giuseppe Montalto, Orazia M. Granata. Estrogen signalling through amphiregulin may be implicated in human hepatocellular carcinoma. hmbci 2011; 5(3): 153 doi: 10.1515/HMBCI.2011.003
|
| 41 |
Bin-Bing S Zhou, Jordan S Fridman, Xiangdong Liu, Steve M Friedman, Robert C Newton, Peggy A Scherle. ADAM proteases, ErbB pathways and cancer. Expert Opinion on Investigational Drugs 2005; 14(6): 591 doi: 10.1517/13543784.14.6.591
|
| 42 |
Carmen Berasain, Maria J. Perugorria, Maria Ujue Latasa, Josefa Castillo, Saioa Goñi, Mónica Santamaría, Jesús Prieto, Matías A. Avila. The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer. Experimental Biology and Medicine 2009; 234(7): 713 doi: 10.3181/0901-MR-12
|
| 43 |
Agnieszka Kalita, Magdalena Sikora-Skrabaka, Ewa Nowakowska-Zajdel. Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets—A Review. Current Issues in Molecular Biology 2023; 45(4): 2917 doi: 10.3390/cimb45040191
|
| 44 |
Kwang-Hoon Chun. Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma. Pharmaceutics 2022; 14(7): 1380 doi: 10.3390/pharmaceutics14071380
|
| 45 |
Jun Arai, Kaku Goto, Yasushi Tanoue, Sayaka Ito, Ryosuke Muroyama, Yasuo Matsubara, Ryo Nakagawa, Yoshimi Kaise, Lay Ahyoung Lim, Hitoshi Yoshida, Naoya Kato. Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells. International Journal of Cancer 2018; 143(10): 2575 doi: 10.1002/ijc.31615
|
| 46 |
Ying Chen, Jun Mo, Xi Jia, Yang He. The B7 Family Member B7-H6: a New Bane of Tumor. Pathology & Oncology Research 2018; 24(4): 717 doi: 10.1007/s12253-017-0357-5
|
| 47 |
Athena Chalaris, Christoph Garbers, Björn Rabe, Stefan Rose-John, Jürgen Scheller. The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer. European Journal of Cell Biology 2011; 90(6-7): 484 doi: 10.1016/j.ejcb.2010.10.007
|
| 48 |
Mark Katakowski, Feng Jiang, XuGuang Zheng, Jorge A. Gutierrez, Alexandra Szalad, Michael Chopp. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Science 2009; 100(9): 1597 doi: 10.1111/j.1349-7006.2009.01221.x
|
| 49 |
Lawrence A. Scheving, Xiuqi Zhang, Mary C. Stevenson, Michael A. Weintraub, Annam Abbasi, Andrea M. Clarke, David W. Threadgill, William E. Russell. Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2015; 309(12): G942 doi: 10.1152/ajpgi.00089.2015
|
| 50 |
Katia Bourd‐Boittin, Laetitia Basset, Dominique Bonnier, Annie L’Helgoualc’h, Michel Samson, Nathalie Théret. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. Journal of Cellular and Molecular Medicine 2009; 13(8a): 1526 doi: 10.1111/j.1582-4934.2009.00787.x
|
| 51 |
Paul Saftig, Karina Reiss. The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: Novel drug targets with therapeutic potential?. European Journal of Cell Biology 2011; 90(6-7): 527 doi: 10.1016/j.ejcb.2010.11.005
|
| 52 |
Jessica Pruessmeyer, Andreas Ludwig. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Seminars in Cell & Developmental Biology 2009; 20(2): 164 doi: 10.1016/j.semcdb.2008.09.005
|
| 53 |
Xue‐wei Yang, Long‐juan Zhang, Xiao‐hui Huang, Lian‐zhou Chen, Qiao Su, Wen‐tao Zeng, Wen Li, Qian Wang. miR‐145 suppresses cell invasion in hepatocellular carcinoma cells: miR‐145 targets ADAM17. Hepatology Research 2014; 44(5): 551 doi: 10.1111/hepr.12152
|
| 54 |
Kim Pedersen, Pier-Davide Angelini, Sirle Laos, Alba Bach-Faig, Matthew P. Cunningham, Cristina Ferrer-Ramón, Antonio Luque-García, Jesús García-Castillo, Josep Lluis Parra-Palau, Maurizio Scaltriti, Santiago Ramón y Cajal, José Baselga, Joaquín Arribas. A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology 2009; 29(12): 3319 doi: 10.1128/MCB.01803-08
|
| 55 |
Yunshu Su, Yuchang Wang, Hongmin Zhou, Lei Lei, Lijun Xu. MicroRNA‐152 targets ADAM17 to suppress NSCLC progression. FEBS Letters 2014; 588(10): 1983 doi: 10.1016/j.febslet.2014.04.022
|
| 56 |
Hidenori Itabashi, Chihaya Maesawa, Hiroki Oikawa, Koji Kotani, Eiichi Sakurai, Kuniyuki Kato, Hideaki Komatsu, Hiroyuki Nitta, Hidenobu Kawamura, Go Wakabayashi, Tomoyuki Masuda. Angiotensin II and epidermal growth factor receptor cross‐talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatology Research 2008; 38(6): 601 doi: 10.1111/j.1872-034X.2007.00304.x
|
| 57 |
Isabel Fabregat, César Roncero, Margarita Fernández. Survival and apoptosis: a dysregulated balance in liver cancer. Liver International 2007; 27(2): 155 doi: 10.1111/j.1478-3231.2006.01409.x
|
| 58 |
Xuguang Zheng, Feng Jiang, Mark Katakowski, Yong Lu, Michael Chopp. ADAM17 promotes glioma cell malignant phenotype. Molecular Carcinogenesis 2012; 51(2): 150 doi: 10.1002/mc.20772
|
| 59 |
Nathalie Théret, Fidaa Bouezzeddine, Fida Azar, Mona Diab-Assaf, Vincent Legagneux. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. Cancers 2021; 13(7): 1563 doi: 10.3390/cancers13071563
|
| 60 |
XIAOHONG LV, YANG LI, MING QIAN, CHENGYUAN MA, HONGYU JING, ZHONGMEI WEN, DONGHUA QIAN. ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer. Molecular Medicine Reports 2014; 9(5): 1935 doi: 10.3892/mmr.2014.2029
|
| 61 |
Tam Vy Le, Ngoc Thien Lam, Phuong D. Nguyen, Quynh Hoa Tran, Dinh-Truong Nguyen, Minh Nam Nguyen. 9th International Conference on the Development of Biomedical Engineering in Vietnam. IFMBE Proceedings 2024; 95: 942 doi: 10.1007/978-3-031-44630-6_75
|